Cannabis Science and Technology® and Cannabis Patient Care™ Partner with Havas ECS to Offer Endocannabinoid Educational Courses
The comprehensive training curriculum is for all levels of students and features three course offerings.
Cannabis Science and Technology®, Cannabis Patient Care™ and Havas ECS are excited to announce a new partnership to bring a comprehensive training curriculum to all levels of students: health care professionals, patients, parents, caregivers and budtenders.
“Education is key to our mission and core values,” said Mike Hennessy Jr., president and CEO of MJH Life Sciences™, the parent company of Cannabis Science and Technology® and Cannabis Patient Care™. “We are thrilled to offer our professional audience the opportunity to become more qualified in understanding the endocannabinoid system and its therapeutic context from an innovative well- credentialed education partner.”
The curriculum features three course offerings, allowing one to learn the basics of the endocannabinoid system or earn continuing medical education (CME) credits in either a three-CME course or a 12-CME course.
“Introduction to Endocannabinoid Medicine” is a foundational course designed to introduce health care professionals to the endocannabinoid system (ECS) and its therapeutic potential. Successful completion of this online learning system confers a total of three AMA PRA Category 1 Credits™ and an Introduction to Endocannabinoid Medicine certificate from Cannabis Patient Care™.
“Certification in Endocannabinoid Medicine” is a comprehensive course for medical professionals interested in gaining accredited certification in endocannabinoid medicine. Successful completion of all four levels modules confers a total of 12 AMA PRA Category 1 Credits™ and a Certificate in Endocannabinoid Medicine from Cannabis Patient Care™.
“Certification in Endocannabinoid Science” is an interactive learning system designed to introduce any learner to the ECS and its potential therapeutic impact. Those successfully completing this module receive an Endocannabinoid Science Certificate from Cannabis Patient Care™.
“Together, with Cannabis Science and Technology® and Cannabis Patient Care™, we are able to offer a comprehensive educational resource that includes exceptional medical cannabis content, thought-provoking condition-specific webcasts, and exam-based endocannabinoid system certification for medical professionals, patients, caregivers, and industry professionals,” said Rob Dhoble, managing director of Havas ECS.
To learn more about the different courses and enroll, please visit www.cannabissciencetech.com/courses.
About Cannabis Science and Technology® and Cannabis Patient Care™
Cannabis Science and Technology® is a multimedia platform that focuses on educating the legal cannabis industry about the science and technology of analytical testing, quality control, extraction and cultivation. The magazine is accompanied by an online component that provides relevant information and tutorials for all members of the cannabis industry.
Cannabis Patient Care™ magazine is an educational resource for patients, doctors, nurses, pharmacists and caregivers on the latest research, benefits and treatment options cannabis provides for a variety of illnesses. Each issue of the publication will focus on a specific disease or ailment that cannabis has been shown to be an effective remedy for. The brand will cover the current research, patient testimonials, medical perspectives and advocacy work. Our mission is to educate the medical community on the viable treatment options patients are experiencing with cannabis and the ongoing research into cannabis and cannabinoids worldwide. Cannabis Science and Technology® and Cannabis Patient Care™ are brands of MJH Life Sciences™, the largest privately held, independent, full-service medical media company in North America dedicated to delivering trusted health care news across multiple channels.
About Havas ECS
Havas ECS (Endocannabinoid Science) is an education and communications services company committed to health professional and consumer understanding of the endocannabinoid system, to better inform self-care, clinical decision making, and evidence-based reimbursement of medical cannabis and cannabinoid therapeutics. Havas ECS offers educational programs that increase participant understanding, and communications solutions that engage health and medical stakeholders on behalf of manufacturers, employers, insurers, governments, and medical groups. For more information, please visit www.havasECS.com. Havas ECS is a division of Havas Health & You. Havas Health & You unites Havas Life, Health4Brands (H4B), Havas Lynx, Havas Life PR and Havas Health Plus, all wholly owned health and communications networks, with the consumer health businesses and practices of Havas Creative Group. Its customer-centric approach has the talent, tenacity and technology that health-and-wellness companies, brands and people need to thrive in today's world. For more information, go to www.HavasHealthandYou.com.
Contacts
Cannabis Science and Technology® Media Contact
Alexandra Ventura, 609-716-7777
aventura@mjhlifesciences.com
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Khan
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
Ep 24, Part I: Data Transparency in Cannabis Testing with Yasha Khan
November 21st 2024Evan Friedmann interviews Yasha Khan, co-founder of MCR Labs, about his journey into the cannabis industry and his efforts to promote transparency and integrity in laboratory practices. Yasha discusses the origins of MCR Labs, which began in Massachusetts to meet the needs of the soon-to-be legal medical cannabis market. He explains the challenges faced, including result manipulation by labs and the impact on public health. Yasha's Freedom of Information Act (FOIA) project aimed to gather testing data from 37 states, revealed significant discrepancies in potency and mold results. Despite some states' reluctance to share data, Yasha has made much of this data public, leading to collaborative research and publications on various aspects of cannabis testing.
